Delivering RNA through exosomes for cancer therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (75)
Show source-provided references
1. Qiu H, Liang J, Yang G, Xie Z, Wang Z, Wang L et al (2024) Application of exosomes in tumor immunity: recent progresses. Front Cell Dev Biol 12:137284710.3389/fcell.2024.1372847 ↗
2. Nema R, Saluja R, Kumar A (2024) Regulation of tumor-immune microenvironment by non-coding RNAs. Front Immunol 15:136288110.3389/fimmu.2024.1362881 ↗
3. Dong P, Taheri M, Wang F (2023) Interplay between RNA-binding proteins and non-coding RNAs in tumor therapeutic resistance. Front oncol 13:120112210.3389/fonc.2023.1201122 ↗
4. Paunovska K, Loughrey D, Dahlman JE (2022) Drug delivery systems for RNA therapeutics. Nat Rev Genet 23(5):265–28010.1038/s41576-021-00439-4 ↗
5. Witwer KW, Wolfram J (2021) Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nat Rev Mater 6(2):103–10610.1038/s41578-020-00277-6 ↗
6. Zhang Y, Chen L, Liu X, Xin X, Meng L, Jin M et al (2019) Advances in research on exosomes as drug delivery vehicles. Acta Pharm Sin 54:1010–1016
7. Nouri Z, Barfar A, Perseh S, Motasadizadeh H, Maghsoudian S, Fatahi Y et al (2024) Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases. J Nanobiotechnol 22(1):46310.1186/s12951-024-02681-4 ↗
8. Couch Y, Buzàs EI, Di Vizio D, Gho YS, Harrison P, Hill AF et al (2021) A brief history of nearly EV-erything-the rise and rise of extracellular vesicles. J Extracell Vesicles 10(14):e1214410.1002/jev2.12144 ↗
9. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N et al (2013) Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 21(1):185–19110.1038/mt.2012.180 ↗
10. Johnstone RM (2005) Revisiting the road to the discovery of exosomes. Blood Cells Mol Dis 34(3):214–21910.1016/j.bcmd.2005.03.002 ↗
11. Tang X, Guo T, Gao X, Wu X, Xing X, Ji J et al (2021) Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol Cancer 20:1–1510.1186/s12943-021-01396-6 ↗
12. Maugeri M, Nawaz M, Papadimitriou A, Angerfors A, Camponeschi A, Na M et al (2019) Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat Commun 10(1):433310.1038/s41467-019-12275-6 ↗
13. Zhang C, ZHOU Z, (2013) Mechanism of vesicle traffic: commentary on the 2013 Nobel Prize in Physiology or Medicine. Res 31(34):22–23
14. Andreu Z, Yáñez-Mó M (2014) Tetraspanins in extracellular vesicle formation and function. Front immunol 5:44210.3389/fimmu.2014.00442 ↗
15. Xu M, Ji J, Jin D, Wu Y, Wu T, Lin R et al (2023) The biogenesis and secretion of exosomes and multivesicular bodies (MVBs): intercellular shuttles and implications in human diseases. Genes Dis 10(5):1894–190710.1016/j.gendis.2022.03.021 ↗
16. Zeng H, Guo S, Ren X, Wu Z, Liu S, Yao X (2023) Current strategies for exosome cargo loading and targeting delivery. Cells 12(10):141610.3390/cells12101416 ↗
17. Record M, Silvente-Poirot S, Poirot M, Wakelam MO (2018) Extracellular vesicles: lipids as key components of their biogenesis and functions. J Lipid Res 59(8):1316–132410.1194/jlr.E086173 ↗
18. Kalluri R, LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Sci 367(6478):eaau697710.1126/science.aau6977 ↗
19. Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA (2022) Exosomes-nature’s lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano 16(11):17802–1784610.1021/acsnano.2c08774 ↗
20. Zhuo Y, Luo Z, Zhu Z, Wang J, Li X, Zhang Z et al (2024) Direct cytosolic delivery of siRNA via cell membrane fusion using cholesterol-enriched exosomes. Nat Nanotechnol 19(12):1858–186810.1038/s41565-024-01785-0 ↗
21. Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA et al (2017) Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546(7659):498–50310.1038/nature22341 ↗
22. Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K et al (2020) Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnology 18:1–1510.1186/s12951-019-0560-5 ↗
23. Kim G, Kim M, Lee Y, Byun JW, Lee M (2020) Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. J Control Release 317:273–28110.1016/j.jconrel.2019.11.009 ↗
24. Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, Osobamiro O et al (2013) Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett 335(1):201–20410.1016/j.canlet.2013.02.019 ↗
25. Kobayashi M, Sawada K, Miyamoto M, Shimizu A, Yamamoto M, Kinose Y et al (2020) Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer. Biochem Biophys Res Commun 527(1):153–16110.1016/j.bbrc.2020.04.076 ↗
26. Liu M, Hu S, Yan N, Popowski KD, Cheng K (2024) Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol 19(4):565–57510.1038/s41565-023-01580-3 ↗
27. Aqil F, Munagala R, Jeyabalan J, Agrawal AK, Kyakulaga AH, Wilcher SA et al (2019) Milk exosomes-natural nanoparticles for siRNA delivery. Cancer Lett 449:186–19510.1016/j.canlet.2019.02.011 ↗
28. Lamichhane TN, Jeyaram A, Patel DB, Parajuli B, Livingston NK, Arumugasaamy N et al (2016) Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication. Cell Mol Bioeng 9:315–32410.1007/s12195-016-0457-4 ↗
29. Xiang X, Chen J, Jiang T, Yan C, Kang Y, Zhang M et al (2023) Milk-derived exosomes carrying siRNA-KEAP1 promote diabetic wound healing by improving oxidative stress. Drug Deliv Transl Res 13(9):2286–229610.1007/s13346-023-01306-x ↗
30. Didiot MC, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K et al (2016) Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther 24(10):1836–184710.1038/mt.2016.126 ↗
31. Yu X, Bai Y, Han B, Ju M, Tang T, Shen L et al (2022) Extracellular vesicle-mediated delivery of circDYM alleviates CUS-induced depressive-like behaviours. J extracell vesicles 11(1):e1218510.1002/jev2.12185 ↗
32. Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV (2013) Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Cell Commun Signal 11:1–1010.1186/1478-811X-11-1 ↗
33. Yang T, Fogarty B, LaForge B, Aziz S, Pham T, Lai L et al (2017) Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer. AAPS J 19:475–48610.1208/s12248-016-0015-y ↗
34. Zhang H, Wang Y, Bai M, Wang J, Zhu K, Liu R et al (2018) Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA. Cancer Sci 109(3):629–64110.1111/cas.13488 ↗
35. Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP et al (2013) Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther 21(1):101–10810.1038/mt.2012.161 ↗
36. Gunassekaran GR, Vadevoo SMP, Baek MC, Lee B (2021) M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials 278:12113710.1016/j.biomaterials.2021.121137 ↗
37. Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE et al (2020) Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev 159:332–34310.1016/j.addr.2020.04.004 ↗
38. Rufino-Ramos D, Albuquerque PR, Carmona V, Perfeito R, Nobre RJ, de Almeida LP (2017) Extracellular vesicles: novel promising delivery systems for therapy of brain diseases. J Control Release 262:247–25810.1016/j.jconrel.2017.07.001 ↗
39. Akbari A, Nazari-Khanamiri F, Ahmadi M, Shoaran M, Rezaie J (2022) Engineered exosomes for tumor-targeted drug delivery: a focus on genetic and chemical functionalization. Pharmaceutics 15(1):6610.3390/pharmaceutics15010066 ↗
40. Ke W, Afonin KA (2021) Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Adv Drug Deliv Rev 176:11383510.1016/j.addr.2021.113835 ↗
41. Huang L, Wu E, Liao J, Wei Z, Wang J, Chen Z (2023) Research advances of engineered exosomes as drug delivery carrier. ACS Omega 8(46):43374–4338710.1021/acsomega.3c04479 ↗
42. Johnsen KB, Gudbergsson JM, Skov MN, Christiansen G, Gurevich L, Moos T et al (2016) Evaluation of electroporation-induced adverse effects on adipose-derived stem cell exosomes. Cytotechnology 68:2125–213810.1007/s10616-016-9952-7 ↗
43. Feng X, Chen X, Zheng X, Zhu H, Qi Q, Liu S et al (2021) Latest trend of milk derived exosomes: cargos, functions, and applications. Front nutr 8:74729410.3389/fnut.2021.747294 ↗
44. Bahadorani M, Nasiri M, Dellinger K, Aravamudhan S, Zadegan R (2024) Engineering exosomes for therapeutic applications: decoding biogenesis, content modification, and cargo loading strategies. Int J Nanomedicine 19:7137–716410.2147/IJN.S464249 ↗
45. Sato YT, Umezaki K, Sawada S, Mukai SA, Sasaki Y, Harada N et al (2016) Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep 6(1):2193310.1038/srep21933 ↗
46. De Jong OG, Van Balkom BWM, Schiffelers RM, Bouten CVC, Verhaar MC (2014) Extracellular vesicles: potential roles in regenerative medicine. Front Immunol 5:608
47. Rezaie J, Ajezi S, Avci ÇB, Karimipour M, Geranmayeh MH, Nourazarian A et al (2018) Exosomes and their application in biomedical field: difficulties and advantages. Mol Neurobiol 55:3372–339310.1007/s12035-017-0582-7 ↗
48. Zhou Y, Zhou G, Tian C, Jiang W, Jin L, Zhang C et al (2016) Exosome-mediated small RNA delivery for gene therapy. WIREs RNA 7(6):758–77110.1002/wrna.1363 ↗
49. Zhang J, Chen B, Gan C, Sun H, Zhang J, Feng L (2023) A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy. Int J Nanomedicine 18:7605–763510.2147/IJN.S436038 ↗
50. Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y et al (2020) Therapeutic siRNA: state of the art. Signal Transduct Target Ther 5(1):10110.1038/s41392-020-0207-x ↗
51. Zogg H, Singh R, Ro S (2022) Current advances in RNA therapeutics for human diseases. Int J Mol Sci 23(5):273610.3390/ijms23052736 ↗
52. Bai J, Duan J, Liu R, Du Y, Luo Q, Cui Y et al (2020) Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells. Asian J Pharm Sci 15(4):461–471
53. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K et al (2010) Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther 17(6):398–40810.1038/cgt.2009.88 ↗
54. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K et al (2013) Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24(4):542–55610.1016/j.ccr.2013.09.008 ↗
55. Binenbaum Y, Fridman E, Yaari Z, Milman N, Schroeder A, Ben David G et al (2018) Transfer of miRNA in macrophage-derived exosomes induces drug resistance in pancreatic adenocarcinoma. Cancer Res 78(18):5287–529910.1158/0008-5472.CAN-18-0124 ↗
56. Duan L, Xu L, Xu X, Qin Z, Zhou X, Xiao Y et al (2021) Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale 13(3):1387–139710.1039/D0NR07622H ↗
57. Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B et al (2018) Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun 9(1):235910.1038/s41467-018-04791-8 ↗
58. Geis-Asteggiante L, Belew AT, Clements VK, Edwards NJ, Ostrand-Rosenberg S, El-Sayed NM et al (2018) Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. J Proteome Res 17(1):486–49810.1021/acs.jproteome.7b00646 ↗
59. Lin H, Yu J, Gu X, Ge S, Fan X (2021) Novel insights into exosomal circular RNAs: Redefining intercellular communication in cancer biology. Clin Transl Med 11(12):e63610.1002/ctm2.636 ↗
60. Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ, Shi GM et al (2020) Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer 19:1–1510.1186/s12943-020-01222-5 ↗
61. Guan X, Zong ZH, Liu Y, Chen S, Wang LL, Zhao Y (2019) circPUM1 promotes tumorigenesis and progression of ovarian cancer by sponging miR-615-5p and miR-6753-5p. Mol Ther-Nucl Acids 18:882–89210.1016/j.omtn.2019.09.032 ↗
62. Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T et al (2020) Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol 14(3):539–55510.1002/1878-0261.12629 ↗
63. Kopp F, Mendell JT (2018) Functional classification and experimental dissection of long noncoding RNAs. Cell 172(3):393–40710.1016/j.cell.2018.01.011 ↗
64. Wang Y, Zhang M, Zhou F (2020) Biological functions and clinical applications of exosomal long non-coding RNAs in cancer. J Cell Mol Med 24(20):11656–1166610.1111/jcmm.15873 ↗
65. Zhang Y, Zhao L, Bi Y, Zhao J, Gao C, Si X et al (2023) The role of lncRNAs and exosomal lncRNAs in cancer metastasis. Biomed Pharmacother 165:11520710.1016/j.biopha.2023.115207 ↗
66. Zang X, Gu J, Zhang J, Shi H, Hou S, Xu X et al (2020) Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression. Cell Death Dis 11(4):21510.1038/s41419-020-2409-0 ↗
67. Chi Y, Xin H, Liu Z (2021) Exosomal lncRNA UCA1 derived from pancreatic stellate cells promotes gemcitabine resistance in pancreatic cancer via the SOCS3/EZH2 axis. Front Oncol 11:67108210.3389/fonc.2021.671082 ↗
68. Sun Z, Yang S, Zhou Q, Wang G, Song J, Li Z et al (2018) Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol Cancer 17:1–910.1186/s12943-018-0831-z ↗
69. Sharma D, Singh A, Wilson C, Swaroop P, Kumar S, Yadav DK et al (2024) Exosomal long non-coding RNA MALAT1: a candidate of liquid biopsy in monitoring of Wilms’ tumor. Pediatr Surg Int 40(1):5710.1007/s00383-023-05626-4 ↗
70. Kang F, Yan Y, Liu Y, Liang Q, Xu Z, Zhu W et al (2023) Unraveling the significance of exosomal circRNAs in cancer therapeutic resistance. Front Pharmacol 14:109317510.3389/fphar.2023.1093175 ↗
71. Yang D, Zhang W, Zhang H, Zhang F, Chen L, Ma L et al (2020) Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics. Theranostics 10(8):368410.7150/thno.41580 ↗
72. Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M et al (2018) Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI insight 3(8):e9926310.1172/jci.insight.99263 ↗
73. Raguraman R, Bhavsar D, Kim D, Ren X, Sikavitsas V, Munshi A et al (2023) Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett 558:21609310.1016/j.canlet.2023.216093 ↗
74. Xing HN, Lu M, Liu YQ, Dong YH, Zheng AP (2022) Research progress of exosomes based targeted delivery of antitumor drugs. APS 12:150–158
75. Alptekin A, Parvin M, Chowdhury HI, Rashid MH, Arbab AS (2022) Engineered exosomes for studies in tumor immunology. Immunol Rev 312(1):76–10210.1111/imr.13107 ↗